The neurotrophic analogue of ACTH(4-9), Org 2766, protects against experimental allergic neuritis.
Demyelinating diseases such as multiple sclerosis or the Guillain-Barré syndrome originate from an autoimmune response resulting in the degradation of myelin and impaired neuronal function. Prophylactic administration of the neurotrophic peptide, H-Met(O2)-Glu-His-Phe-D-Lys-Phe-OH [an ACTH(4-9) analogue], to rats with experimental allergic neuritis, a model for the Guillain-Barré syndrome, markedly suppresses the clinical symptoms, protects against loss of motor coordination and prevents the degeneration of myelinated axons in the affected peripheral nerve. Therefore, this peptide may provide a new approach to the therapy of peripheral demyelinating polyneuropathies.
Duckers
H J
HJ
Department of Medical Pharmacology, Rudolf Magnus Institute, University of Utrecht, The Netherlands.
Verhaagen
J
J
Gispen
W H
WH
D000324:Adrenocorticotropic Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D005260:Female; D008124:Locomotion; D009068:Movement / Q000187:drug effects; D009444:Neuritis, Autoimmune, Experimental / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D010446:Peptide Fragments / Q000627:therapeutic use*; D051381:Rats; D011917:Rats, Inbred Lew; D015431:Weight Loss
D010446:Peptide Fragments; C013765:Org 2766; D000324:Adrenocorticotropic Hormone